企业QQ
官方微信
| Adenovirus | HCV | Malaria | SIV |
| Autoimmunity | HIV | miHAg | Trypanosoma |
| Cancer | HPV | ModelAntigen | Tuberculosis |
| Chlamydia | HTLV | Negative | Vaccinia |
| CMV | Influenza | Other | VSV |
| EBV | LCMV | RSV | WestNileVirus |
| HBV | Listeria | SendaiVirus | YellowFever |
| ALLELE | PEPTIDECODE | PEPTIDESEQUENCE | Stock/ Available | EPITOPEORIGIN |
| A*01:01 | 686 | TDLGQNLLY | A | Adenovirus5Hexon886-894 |
| A*24:02 | 684 | TYFSLNNKF | A | Adenovirus5Hexon37-45 |
| B*07:02 | 989 | KPYSGTAYNAL | A | AdenovirusHexon114-124 |
| ALLELE | PEPTIDECODE | PEPTIDESEQUENCE | Stock/ Available | EPITOPEORIGIN |
| A*02:01 | 151 | KLQVFLIVL | A | T1DDiabeteshumanpreproisletamyloidpolypeptideppIAPP5-13 |
| A*02:01 | 954 | LNIDLLWSV | A | T1DDiabetesIGRP228–236 |
| A*02:01 | 851 | HLVEALYLV | A | InsulinBchain10-18 |
| A*02:01 | 393 | VMNILLQYV | A | GAD65114-123 |
| A*02:01 | 470 | SLSRFSWGA | A | Myelinbasicprotein110-118 |
| A*02:01 | 1904 | VLFGLGFAI | A | T1DDiabetesIGRP265-273 |
| ALLELE | PEPTIDECODE | PEPTIDESEQUENCE | Stock/ Available | EPITOPEORIGIN |
| A*01:01 | 307 | KSDICTDEY | A | Tyrosinase243-251(244S) |
| A*02:01 | 2291 | AILALLPAL | A | ProstateStemCellAntigen(PSCA)105-133 |
| A*02:01 | 1920 | ALLTSRLRFI | A | TelomeraseReverseTranscriptase(hTRT)615-624 |
| A*02:01 | 2083 | FLAEDALNTV | A | EpithelialDiscoidinDomainReceptor1(EDDR1)867-876 |
| A*02:01 | 2079 | FLYDDNQRV | A | TopoisomeraseII-alpha-b828-836 |
| A*02:01 | 1386 | GLAPPQHLIRV | A | p53187-197 |
| A*02:01 | 468 | ILSLELMKL | A | Receptorforhyaluronicacid–mediated motility(RHAMM)165-173 |
| A*02:01 | 1464 | LTLGEFLKL | A | Survivin-3A96-104 |
| A*02:01 | 2299 | SLPPPGTRV | A | p53149-157 |
| A*02:01 | 1403 | VIMPCSWWV | A | Chondromodulin-I319-327 |
| A*02:01 | 1201 | YMCSFLFNL | A | EwingTumorEZH2666-674 |
| A*02:01 | 061 | YMDGTMSQV | A | Tyrosinase369-377(371D) |
| A*02:01 | 447 | YLQVNSLQTV | A | TelomeraseReverseTranscriptase(hTRT)988-997 |
| A*02:01 | 859 | KLQDASAEV | A | HM1.24-aa126-134 |
| A*02:01 | 329 | ILLWQPIPV | A | ProstaticAcidPhosphatase-3(PAP-3)135-143 |
| A*02:01 | 560 | GLMEEMSAL | A | HumanMenaprotein(overexpressedinbreastcancer) |
| A*02:01 | 813 | FVGEFFTDV | A | GPC3144-152(overexpressedinhepatocellularcarcinoma) |
| A*02:01 | 075 | YLSGANLNL | S | CarcinogenicEmbryonicAntigen(CEA)571-579 |
| A*02:01 | 157 | VLYRYGSFSV | A | gp100(pmel17)476-485 |
| A*02:01 | 250 | VLQELNVTV | S | LeukocyteProteinase-3(Wegener"sautoantigen)169-177 |
| A*02:01 | 097 | VISNDVCAQV | A | ProstateSpecificAntigen-1(PSA-1)154-163 |
| A*02:01 | 390 | SLLMWITQV | A | NY-ESO-1157-165 |
| A*02:01 | 212 | RLLQETELV | S | HER-2/neu689-697 |
| A*02:01 | 810 | LIAHNQVRQV | A | HER-2/neu85–94 |
| A*02:01 | 690 | LLHETDSAV | A | PSMA/PSM-P14-12 |
| A*02:01 | 599 | ALDVYNGLL | A | Prostaticacidphosphataseprecursor(PAP)299-307 |
| A*02:01 | 645 | YLNTVQPTCV | A | EGF-R1138-1147 |
| A*02:01 | 781 | VLDGLDVLL | A | PRAME100-108 |
| A*02:01 | 689 | VLAGGFFLL | A | PSMA27-38 |
| A*02:01 | 394 | YLFFYRKSV | A | mTERT572-580 |
| A*02:01 | 034 | FLWGPRALV | A | MAGEA3271-279 |
| A*02:01 | 646 | KLFGTSGQKT | A | EGF-R-479350-359 |
| A*02:01 | 915 | TLPGYPPHV | A | PAX-5311-319 |
| A*02:01 | 1056 | SLFLGILSV | A | CD20188-196(Bcellmalignancies) |
| A*02:01 | 117 | RLVDDFLLV | A | TelomeraseReverseTranscriptase865-873 |
| A*02:01 | 208 | LLLLTVLTV | A | MUC-112-20 |
| A*02:01 | 205 | LLGRNSFEV | A | p53264-272 |
| A*02:01 | 600 | ALFDIESKV | A | PSMP2(prostate) |
| A*02:01 | 1013 | FLGYLILGV | A | ProstaticAcidPhosphatase-3(PAP-3) |
| A*02:01 | 561 | TMNGSKSPV | A | hMena502-510 |
| A*02:01 | 391 | LMLGEFLKL | S | Survivin96-104 |
| A*02:01 | 338 | QLCPICRAPV | A | Livin/ML-IAP280175-184 |
| A*02:01 | 1181 | SLSEKTVLL | A | CD59glycoproteinprecursor106-114 |
| A*02:01 | 958 | SLVDVMPWL | A | Cytochromep4501B1239-248 |
| A*02:01 | 214 | KIFGSLAFL | A | HER-2/neu369-377 |
| A*02:01 | 046 | IMDQVPFSV | S | gp100(pmel17)209-217 |
| A*02:01 | 210 | ILHNGAYSL | A | HER-2/neu435-443 |
| A*02:01 | 085 | ILAKFLHWL | S | Telomerase540-548 |
| A*02:01 | 249 | HLSTAFARV | A | G250(renalcellcarcinoma)217-225 |
| A*02:01 | 125 | GVLVGVALI | A | CarcinogenicEmbryonicAntigen(CEA)694-702 |
| A*02:01 | 527 | ALYVDSLFFL | A | PRAMEPRA300–309 |
| A*02:01 | 405 | KLQCVDLHV | A | ProstateSpecificAntigen146-154 |
| A*02:01 | 086 | ALQPGTALL | A | ProstateStemCellAntigen(PSCA)14-22 |
| A*02:01 | 302 | KVAELVHFL | A | MAGEA3112-120 |
| A*02:01 | 057 | KTWGQYWQV | A | gp100(pmel17)154-162 |
| A*02:01 | 389 | GLYDGMEHL | A | MAGEA-10254-262 |
| A*02:01 | 404 | FLTPKKLQCV | A | ProstateSpecificAntigen-1(PSA-1)141-150 |
| A*02:01 | 082 | ELAGIGILTV | s | MelanA/MART26-35 |
| A*02:01 | 171 | KVLEYVIKV | A | MAGEA1278-286 |
| A*02:01 | 2293 | GLQHWVPEL | A | BA46(Lactadherin)97-106 |
| A*02:01 | 2294 | GVRGRVEEI | A | bcr-ablfusionprotein |
| A*02:01 | 048 | YLSGADLNL | A | Carcinoembryonicantigen(CEA)-derivedpeptideCAP1-6D |
| A*02:01 | 2296 | ITDQVPFSV | A | gp100(pmel)209-217 |
| A*02:01 | 047 | YLEPGPVTV | A | gp100(pmel)280-288(288V) |
| A*02:01 | 2301 | YLQLVFGIEV | A | MAGEA2157-166 |
| A*02:01 | 2298 | KVAEELVHFL | A | MAGEA3112-120(alternativeversion) |
| A*02:01 | 049 | SLLMWITQC | A | NY-ESO-1157-165(9C) |
| A*02:01 | 2300 | YLGSYGFRL | A | p53103-111 |
| A*02:01 | 2297 | KLCPVQLWV | A | p53139-147 |
| A*02:01 | 654 | RMPEAAPPV | A | p5365-73 |
| A*02:01 | 1787 | RLTSRVKAL | A | TelomerareReverseTranscriptase(hTRT)653-661 |
| A*02:01 | 1786 | GLLGASVLGL | A | TelomeraseReverseTranscriptase(hTRT)674-683 |
| A*02:01 | 381 | LLLTVLTVV | A | TumorMucinAntigen13-21 |
| A*03:01 | 118 | ALLAVGATK | A | gp100(pmel17)17-25 |
| A*03:01 | 264 | ATGFKQSSK | A | bcr-abl210kDfusionprotein259-269 |
| A*03:01 | 087 | KQSSKALQR | S | bcr-abl210kDfusionprotein21-29 |
| A*03:01 | 541 | RISTFKNWPK | A | Survivin-3A18-27(27K) |
| A*24:02 | 416 | EYLQLVFGI | A | MAGEA2156-164 |
| A*24:02 | 421 | TFPDLESEF | A | MAGEA397-105 |
| A*24:02 | 209 | TYACFVSNL | A | CarcinogenicEmbryonicAntigen(CEA)652-660 |
| A*24:02 | 417 | TYLPTNASL | A | HER-2/neu63-71 |
| A*24:02 | 418 | VYGFVRACL | A | Telomerasereversetranscriptase(hTRT)461-469 |
| A*24:02 | 230 | AFLPWHRLF | A | Tyrosinase188-196 |
| A*24:02 | 2303 | CYASGWGSI | A | ProstateSpecificAntigen-1153-161 |
| A*24:02 | 238 | VYFFLPDHL | A | gp100-intron4170-178 |
| A*24:02 | 1806 | RYCNLEGPPI | A | Lymphocyteantigen6complexlocusK(LY6K)177-186 |
| A*24:02 | 2302 | AYACNTSTL | A | Survivin80-88 |
| B*07:02 | 2304 | LPWHRLFLL | A | Tyrosinase208-216 |
| B*08:01 | 094 | GFKQSSKAL | A | bcr-abl210kDfusionprotein19-27 |
| B*35:01 | 2307 | MPFATPMEA | A | NY-ESO-194-102 |
| H-2Db | 1731 | ATFKNWPFL | A | MurineSurvivin20-28 |
| H-2Db | 695 | Abu-Abu-L-Abu-LTVFL | A | Moloneymurinesarcomavirus(MoMSV)GagL85–93 |
| H-2Db | 2199 | FSNSTNDILI | A | VEGFR2/KDRfragment1614-624 |
| H-2Db | 1333 | KVPRNQDWL | A | gp100(pmel17)25-33 |
| H-2Kb | 185 | SVYDFFVWL | A | Tyrosinaserelatedprotein-2180-188 |
| H-2Kb | 351 | HNTQYCNL | A | MAGEA55-12 |
| H-2Kb | 2311 | TVSEFLKL | A | MurineSurvivin97-104 |
| H-2Kd | 0275 | DYWGQGTEL | A | SurfaceIgG(sA20-Ig)ofA20106-114 |
| H-2Kd | 814 | EYILSLEEL | A | GPC3298-306 |
| H-2Kd | 343 | TYVPANASL | A | neu/HER-2/Erbb2proto-oncoprotein66-74 |
| H-2Ld | 150 | LPYLGWLVF | A | TumourAntigenP81535-43 |